CorMedix IncNASDAQ:CRMD
- LAST PRICE5.2650
- TODAY'S CHANGE (%)0.1450 (2.8320%)
- Bid / Lots5.2600/ 2
- Ask / Lots5.2700/ 3
- Open / Previous Close5.1800 / 5.1200
- Day Range
- 52 Week Range
- Volume246,305
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRMD |
|---|---|---|
| 09:32 ET | 12930 | 5.17 |
| 09:34 ET | 3862 | 5.19 |
| 09:36 ET | 3995 | 5.17 |
| 09:38 ET | 2344 | 5.18 |
| 09:39 ET | 3239 | 5.2 |
| 09:41 ET | 1800 | 5.2099 |
| 09:43 ET | 7819 | 5.245 |
| 09:45 ET | 6795 | 5.285 |
| 09:48 ET | 14290 | 5.23 |
| 09:50 ET | 7941 | 5.22 |
| 09:52 ET | 5996 | 5.23 |
| 09:54 ET | 794 | 5.22 |
| 09:56 ET | 1600 | 5.2 |
| 09:57 ET | 1784 | 5.19 |
| 09:59 ET | 6223 | 5.16 |
| 10:01 ET | 5733 | 5.1699 |
| 10:03 ET | 2138 | 5.17 |
| 10:06 ET | 2543 | 5.145 |
| 10:08 ET | 1584 | 5.14 |
| 10:10 ET | 3425 | 5.145 |
| 10:12 ET | 350 | 5.14 |
| 10:17 ET | 450 | 5.1799 |
| 10:19 ET | 100 | 5.175 |
| 10:21 ET | 2199 | 5.174 |
| 10:24 ET | 580 | 5.17 |
| 10:28 ET | 3170 | 5.15 |
| 10:30 ET | 6112 | 5.18 |
| 10:32 ET | 5284 | 5.184 |
| 10:33 ET | 200 | 5.18 |
| 10:35 ET | 500 | 5.1825 |
| 10:37 ET | 600 | 5.175 |
| 10:42 ET | 4281 | 5.1845 |
| 10:44 ET | 5911 | 5.22 |
| 10:48 ET | 600 | 5.24 |
| 10:50 ET | 1700 | 5.2461 |
| 10:51 ET | 2935 | 5.2603 |
| 10:53 ET | 1514 | 5.26 |
| 10:57 ET | 100 | 5.26 |
| 11:00 ET | 400 | 5.26 |
| 11:02 ET | 100 | 5.2601 |
| 11:04 ET | 2238 | 5.285 |
| 11:06 ET | 2748 | 5.2701 |
| 11:08 ET | 3500 | 5.275 |
| 11:09 ET | 5180 | 5.29 |
| 11:11 ET | 200 | 5.295 |
| 11:13 ET | 3793 | 5.3199 |
| 11:15 ET | 600 | 5.32 |
| 11:18 ET | 1411 | 5.325 |
| 11:20 ET | 200 | 5.33 |
| 11:22 ET | 330 | 5.34 |
| 11:24 ET | 11921 | 5.33 |
| 11:26 ET | 800 | 5.3 |
| 11:27 ET | 570 | 5.32 |
| 11:31 ET | 100 | 5.313 |
| 11:33 ET | 433 | 5.3 |
| 11:36 ET | 9792 | 5.305 |
| 11:38 ET | 100 | 5.31 |
| 11:40 ET | 1200 | 5.31 |
| 11:42 ET | 6800 | 5.31 |
| 11:44 ET | 100 | 5.32 |
| 11:45 ET | 2621 | 5.315 |
| 11:47 ET | 1100 | 5.32 |
| 11:49 ET | 300 | 5.315 |
| 11:51 ET | 3100 | 5.31 |
| 11:54 ET | 4163 | 5.275 |
| 11:56 ET | 328 | 5.275 |
| 12:00 ET | 400 | 5.285 |
| 12:02 ET | 6400 | 5.2799 |
| 12:03 ET | 487 | 5.26 |
| 12:05 ET | 260 | 5.255 |
| 12:07 ET | 1291 | 5.264 |
| 12:09 ET | 1000 | 5.265 |
| 12:14 ET | 445 | 5.265 |
Today
May 13, 2024
DJ CorMedix Price Target Maintained With a $10.00/Share by Needham, from 5:42AM ET on Monday May 13, 2024 by Dow Jones
5:42AM ET on Monday May 13, 2024 by Dow Jones
May 10, 2024
CorMedix Inc. to Participate in Two Upcoming Investor Conferences, from 8:30AM ET on Friday May 10, 2024 by Dow Jones
8:30AM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones*DJ CorMedix 1Q Loss/Shr 25c >CRMD, from 7:30AM ET on Thursday May 09, 2024 by Dow Jones
7:30AM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
CorMedix Inc | 281.5M | -5.7x | --- |
Cipla Ltd | 14.4B | 0.0x | --- |
Zevra Therapeutics Inc | 195.0M | -3.4x | --- |
Dbv Technologies SA | 129.7M | -1.4x | --- |
Assembly Biosciences Inc | 83.1M | -1.3x | --- |
Incannex Healthcare Inc | 44.1M | 0.0x | --- |
Company Information
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Contact Information
- Headquarters
- 300 Connell Drive, Suite 4200BERKELEY HEIGHTS, NJ, United States 07922
- Phone
- 908-517-9500
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Myron Kaplan
- Chief Executive Officer, Director
- Joseph Todisco
- Chief Financial Officer, Executive Vice President
- Matthew David
- Executive Vice President, Head of Clinical and Medical Affairs
- Elizabeth Massonhurlburt
- Executive Vice President, Chief Commercial Officer
- Erin Mistry
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $281.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 55.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.72 |
EPS | $-0.93 |
Book Value | $1.28 |
P/E Ratio | -5.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
